Literature DB >> 1687120

Sick population--treated population: the need for a better definition. The VALIDATA Group.

J P Collet1, J P Boissel.   

Abstract

There are many questions concerned with therapy and its application. Depending on the perspective of the study there can be several "populations" which, when considered individually, may give different, or even inconsistent conclusions. These populations are: the sick population, the therapist's target population, the eligible population for a study, the study population, the treatment target population, and the treatment distribution population. Semantic precision, giving a better definition of the populations, is an essential prerequirement in order to tackle scientifically all the facets of assessment of therapy. Accurate definition will help in the study of areas as varied as the methodology, the therapeutic studies, the validity of the recommendations made, the impact of these recommendations on prescription, and finally, the consequences of the prescription in terms of public health (clinical and economical). Several examples are given to show the relationship between these populations and the importance of an accurate definition for each. Guidelines for the identification of these populations are provided. In this overall approach to therapy, epidemiology is an essential, complementary tool to clinical trials.

Mesh:

Substances:

Year:  1991        PMID: 1687120     DOI: 10.1007/bf00314951

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol.

Authors:  J P Boissel; A Leizorovicz; H Picolet; J C Peyrieux
Journal:  Am J Cardiol       Date:  1990-08-01       Impact factor: 2.778

2.  Was the international randomized trial of extracranial-intracranial arterial bypass representative of the population at risk?

Authors:  T M Sundt
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

3.  Post-marketing studies of drug efficacy: why?

Authors:  B L Strom; K L Melmon; O S Miettinen
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965

4.  A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1982-09-16       Impact factor: 91.245

5.  Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial.

Authors: 
Journal:  N Engl J Med       Date:  1985-11-07       Impact factor: 91.245

6.  Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer.

Authors:  K M Taylor; R G Margolese; C L Soskolne
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

7.  Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

8.  Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log.

Authors:  C P Hunter; R W Frelick; A R Feldman; A R Bavier; W H Dunlap; L Ford; D Henson; D Macfarlane; C R Smart; R Yancik
Journal:  Cancer Treat Rep       Date:  1987-06

9.  The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1988-01       Impact factor: 29.983

  9 in total
  3 in total

1.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

2.  Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.

Authors:  S G Bowes; R J Dobbs; M Henley; A Charlett; C J O'Neill; P W Nicholson; A G Purkiss; C Weller; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Revisiting the relationship between baseline risk and risk under treatment.

Authors:  Hao Wang; Jean-Pierre Boissel; Patrice Nony
Journal:  Emerg Themes Epidemiol       Date:  2009-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.